




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/11, 9/00, C07H 21/00, A61K 31/70 // C12Q 1/68	A1	(11) International Publication Number: WO 98/58057 (43) International Publication Date: 23 December 1998 (23.12.98)
(21) International Application Number: PCT/US98/12570 (22) International Filing Date: 16 June 1998 (16.06.98) (30) Priority Data: 879,078 19 June 1997 (19.06.97) US (71) Applicant: INNOVIR LABORATORIES, INC. [US/US]; 510 East 73rd Street, New York, NY 10021 (US). (72) Inventors: LUDWIG, János; Herzberger Landstrasse 43b, D-37085 Göttingen (DE). SPROAT, Brian, S.; Am Antonsberg 10, D-37139 Adelebsen (DE). (74) Agents: PABST, Patrea, L. et al.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS



(57) Abstract

Disclosed are compositions inducing cleavage of an RNA substrate, as well as their use for inducing cleavage of RNA substrates *in vitro* and *in vivo*. The compositions contain part of an active center, with the other part of the active center provided by the RNA substrate. The subunits of the active center region of the compositions are nucleotides and/or nucleotide analogues. The disclosed compositions also have flanking regions contributing to the formation of a specific hybridization with an RNA substrate. Preferred compositions form, in combination with an RNA substrate, a structure resembling a hammerhead structure. The active center of the disclosed compositions is characterized by the presence of I^{15.1} which allows cleavage of RNA substrates having C^{16.1}.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS

Background of the Invention

The present invention is in the field of compositions having RNA-cleavage activity.

Hammerhead ribozymes are an example of catalytic RNA molecules which are able to recognize and cleave a given specific RNA substrate (Hotchins *et al.*, *Nucleic Acids Res.* 14:3627 (1986); Keese and Symons, in *Viroids and viroid - like pathogens* (J.J. Semanchik, publ., CRC-Press, Boca Raton, Florida, 1987), pages 1-47). The catalytic center of hammerhead ribozymes is flanked by three stems and can be formed by adjacent sequence regions of the RNA or also by regions which are separated from one another by many nucleotides. Figure 1 shows a diagram of such a catalytically active hammerhead structure. The stems have been denoted I, II and III. The nucleotides are numbered according to the standard nomenclature for hammerhead ribozymes (Hertel *et al.*, *Nucleic Acids Res.* 20:3252 (1992)). In this nomenclature, bases are denoted by a number which relates their position relative to the 5' side of the cleavage site. Furthermore, each base that is involved in a stem or loop region has an additional designation (which is denoted by a decimal point and then another number) that defines the position of that base within the stem or loop. A designation of N^{11.3} would indicate that this base is involved in a paired region and that it is the third base in that stem going away for the core region. This accepted convention for describing hammerhead derived ribozymes allows for the nucleotides involved in the core of the enzyme to always have the same number relative to all of the other nucleotides. The size of the stems involved in substrate binding or core formation can be any size and of any sequence, and the position of A⁹, for example, will remain the same relative to all of the other core nucleotides. Nucleotides designated, for example, N¹² or N^{9^} represent an inserted nucleotide where the position of the caret (^) relative to the number denotes whether the insertion is before or after the indicated nucleotide. Thus, N¹² represents a nucleotide inserted before nucleotide

position 12, and N^9 represent a nucleotide inserted after nucleotide position 9.

The consensus sequence of the catalytic core structure is described by Ruffner and Uhlenbeck (*Nucleic Acids Res.* 18:6025-6029 (1990)). Perriman
5 *et al.* (*Gene* 113:157-163 (1992)) have meanwhile shown that this structure can also contain variations, for example, naturally occurring nucleotide insertions such as N^9 and N^{12} . Thus, the positive strand of the satellite RNA of the tobacco ring-spot virus does not contain any of the two nucleotide insertions while the +RNA strand of the virusoid of the lucerne
10 transient streak virus (vLTSV) contains a $N^9 = U$ insertion which can be mutated to C or G without loss of activity (Sheldon and Symons, *Nucleic Acids Res.* 17:5679-5685 (1989)). Furthermore, in this special case, $N^7 = A$ and $R^{15.1} = A$. On the other hand, the minus strand of the carnation stunt associated viroid (- CarSV) is quite unusual since it contains both nucleotide
15 insertions, that is $N^{12} = A$ and $N^9 = C$ (Hernandez *et al.*, *Nucleic Acids Res.* 20:6323-6329 (1992)). In this viroid $N^7 = A$ and $R^{15.1} = A$. In addition, this special hammerhead structure exhibits a very effective self-catalytic cleavage despite the more open central stem.

Possible uses of hammerhead ribozymes include, for example,
20 generation of RNA restriction enzymes and the specific inactivation of the expression of genes in, for example, animal, human or plant cells and prokaryotes, yeasts and plasmodia. A particular biomedical interest is based on the fact that many diseases, including many forms of tumors, are related to the overexpression of specific genes. Inactivating such genes by cleaving
25 the associated mRNA represents a possible way to control and eventually treat such diseases. Moreover there is a great need to develop antiviral, antibacterial and antifungal pharmaceutical agents. Ribozymes have potential as such anti-infective agents since viral expression can be blocked selectively by cleaving viral or microbial RNA molecules vital to the survival of the
30 organism.

In addition to needing the correct hybridizing sequences for substrate binding, substrates for hammerhead ribozymes have been shown to strongly

prefer the triplet $N^{16.2}U^{16.1}H^{17}$ where N can be any nucleotide, U is uridine, and H is either adenosine, cytidine, or uridine (Koizumi *et al.*, *FEBS Lett.* 228, 228-230 (1988); Ruffner *et al.*, *Biochemistry* 29, 10695-10702 (1990); Perriman *et al.*, *Gene* 113, 157-163 (1992)). The fact that changes to this
5 general rule for substrate specificity result in non-functional substrates implies that there are "non core compatible" structures which are formed when substrates are provided which deviate from the stated requirements. Evidence along these lines was recently reported by Uhlenbeck and co-workers (*Biochemistry* 36:1108-1114 (1997)) when they demonstrated that the
10 substitution of a G at position 17 caused a functionally catastrophic base pair between G^{17} and C^3 to form, both preventing the correct orientation of the scissile bond for cleavage and the needed tertiary interactions of C^3 (Murray *et al.*, *Biochem. J.* 311:487-494 (1995)). The strong preference for a U at position 16.1 may exist for similar reasons. Many experiments have been
15 done in an attempt to isolate ribozymes which are able to efficiently relieve the requirement of a U at position 16.1, however, attempts to find hammerhead type ribozymes which can cleave substrates having a base other than a U at position 16.1 have proven impossible (Perriman *et al.*, *Gene* 113, 157-163 (1992)).

20 Efficient catalytic molecules with reduced or altered requirements in the cleavage region are highly desirable because their isolation would greatly increase the number of available target sequences that molecules of this type could cleave. For example, it would be desirable to have a ribozyme variant that could efficiently cleave substrates containing triplets other than
25 $N^{16.2}U^{16.1}H^{17}$ since this would increase the number of potential target cleavage sites.

Chemically modified oligonucleotides which contain a block of deoxyribonucleotides in the middle region of the molecule have potential as pharmaceutical agents for the specific inactivation of the expression of genes
30 (Giles *et al.*, *Nucleic Acids Res.* 20:763-770 (1992)). These oligonucleotides can form a hybrid DNA-RNA duplex in which the DNA bound RNA strand is degraded by RNase H. Such oligonucleotides are considered to promote

cleavage of the RNA and so cannot be characterized as having an RNA-cleaving activity nor as cleaving an RNA molecule (the RNase H is cleaving). A significant disadvantage of these oligonucleotides for *in vivo* applications is their low specificity, since hybrid formation, and thus
5 cleavage, can also take place at undesired positions on the RNA molecules.

Previous attempts to recombinantly express catalytically active RNA molecules in the cell by transfecting the cell with an appropriate gene have not proven to be very effective since a very high expression was necessary to inactivate specific RNA substrates. In addition the vector systems which are
10 available now cannot generally be applied. Furthermore, unmodified ribozymes cannot be administered directly due to the sensitivity of RNA to degradation by RNases and their interactions with proteins. Thus, chemically modified active substances have to be used in order to administer hammerhead ribozymes exogenously (discussed, for example, by Heidenreich
15 *et al.*, *J. Biol. Chem.* 269:2131-2138 (1994); Kiehntopf *et al.*, *EMBO J.* 13:4645-4652 (1994); Paoletta *et al.*, *EMBO J.* 11:1913-1919 (1992); and Usman *et al.*, *Nucleic Acids Symp. Ser.* 31:163-164 (1994)).

U.S. Patent No. 5,334,711 describes such chemically modified active substances based on synthetic catalytic oligonucleotide structures with a
20 length of 35 to 40 nucleotides which are suitable for cleaving a nucleic acid target sequence and contain modified nucleotides that contain an optionally substituted alkyl, alkenyl or alkynyl group with 1 - 10 carbon atoms at the 2'-O atom of the ribose. These oligonucleotides contain modified nucleotide building blocks and form a structure resembling a hammerhead structure.
25 These oligonucleotides are able to cleave specific RNA substrates. Examples of oligonucleotides are described having an active center which has a length of 14 nucleotides and which contains several ribonucleotides. These ribonucleotides increase the sensitivity of the oligonucleotide to enzymes which cleave RNA. A further disadvantage is the length of the active center
30 which can often lead to unspecific hybridization.

WO 95/11304 describes RNA-cleaving nucleic acids with an active center that is free of ribonucleotide building blocks but instead contains

deoxyribonucleotides. However, the deoxyribonucleotides used in the active center result in a very low RNA cleavage activity. Thus, it was reported that a 13-mer deoxyribozyme of the "GAAA" type based on LTSV was not able to cleave a 41-mer oligoribonucleotide substrate while the corresponding 13-mer ribozyme exhibited catalytic activity (Jeffries and Symons, *Nucleic Acids Res.* 17:1371-1377 (1989)).

WO 97/18312 describes oligomers which contain only part of a catalytic core resembling a hammerhead catalytic core. These oligomers, when associated with an RNA substrate having a motif resembling the complementary part of a catalytic core, induce cleavage of the RNA substrate. The RNA substrates for use with these oligomers all have a U at position 16.1.

The use of a large number of deoxyribonucleotides in the hybridization arms or in the active center can lead to a loss of specificity due to an activation of RNase H since sequences which are related to the desired target sequence can also be cleaved. Moreover, catalytic DNA oligomers are not particularly well suited for *in vivo* applications due to interactions with proteins, and lack of resistance to degradation by nucleases.

The shortest ribozymes that have been previously used have a minimum length of $15+N+M$ nucleotides, the active center being 15 nucleotides long and N and M being the length of the recognition sequences (Benseler *et al.*, *J. Am. Chem. Soc.* 115:8483-8484 (1993)). Such ribozymes also contain ribonucleotides in at least five positions of the catalytic center (Paolella *et al.*, *EMBO J.* 11:1913-1919 (1992), and Yang *et al.*, *Biochemistry* 31:5005-5009 (1992)).

It is therefore an object of the present invention to provide compositions that induce cleavage of RNA, and in particular to provide oligomers that induce cleavage of RNA and which at the same time have a high stability, activity, and specificity.

It is another object of the present invention to provide compositions that induce cleavage of RNA substrates having a cleavage site triplet other than $N^{16.2}U^{16.1}H^{17}$.

Summary of the Invention

Disclosed are compositions inducing cleavage of an RNA substrate, as well as their use for inducing cleavage of RNA substrates *in vitro* and *in vivo*. The compositions contain part of an active center, with the other part of the active center provided by the RNA substrate. The subunits of the active center region of the compositions are nucleotides and/or nucleotide analogues. The disclosed compositions also have flanking regions contributing to the formation of a specific hybridization with an RNA substrate. Preferred compositions form, in combination with an RNA substrate, a structure resembling a hammerhead structure. The active center of the disclosed compositions is characterized by the presence of I^{15.1} which allows cleavage of RNA substrates having C^{16.1}.

Brief Description of the Drawings

Figure 1 is a diagram of a hammerhead structure and the corresponding nomenclature (SEQ ID NO:1). Cleavage occurs between H¹⁷ and N^{1.1} to generate the 2'-3'-cyclic phosphate at H¹⁷.

Figure 2 is a diagram of an RNA substrate (SEQ ID NO:3) in association with an example of an oligomer (SEQ ID NO:2) that induces cleavage of the RNA substrate. The structure formed by the oligomer and the substrate resembles the structure of a hammerhead ribozyme, with each providing a part of the elements corresponding to the catalytic core. In this case, the substrate makes up half of stems II and III and all of stem I, and loops II and III are not present. Cleavage occurs 3' of H¹⁷.

Figure 3 is a diagram showing the interaction of the A^{15.1}-U^{16.1} base pair in hammerhead ribozymes (top), and the predicted isostructural interaction of a I^{15.1}-C^{16.1} base pair (bottom) that replaces the A^{15.1}-U^{16.1} base pair.

Figure 4A is a diagram of an RNA substrate (SEQ ID NO:22) in association with an example of an oligomer (SEQ ID NO:23) that induces cleavage of the RNA substrate.

Figure 4B is a graph showing the time course of cleavage of the RNA substrate shown in SEQ ID NO:22.

Figure 5A is a diagram of an RNA substrate (SEQ ID NO:24) in association with an example of an oligomer (SEQ ID NO:25) that induces cleavage of the RNA substrate.

5 Figure 5B is a graph showing the time course of cleavage of the RNA substrate shown in SEQ ID NO:24.

Figure 6A is a diagram of an RNA substrate (SEQ ID NO:26) in association with an example of an oligomer (SEQ ID NO:27) that induces cleavage of the RNA substrate.

10 Figure 6B is a graph showing the time course of cleavage of the RNA substrate shown in SEQ ID NO:26.

Figure 7A is a diagram of an RNA substrate (SEQ ID NO:28) in association with an example of an oligomer (SEQ ID NO:29) that induces cleavage of the RNA substrate.

15 Figure 7B is a graph showing the time course of cleavage of the RNA substrate shown in SEQ ID NO:28.

Figure 8A is a diagram of an RNA substrate (SEQ ID NO:30) in association with an example of an oligomer (SEQ ID NO:31) that induces cleavage of the RNA substrate.

20 Figure 8B is a graph showing the time course of cleavage of the RNA substrate shown in SEQ ID NO:30.

Detailed Description of the Invention

Disclosed are compositions inducing cleavage of an RNA substrate, as well as their use for inducing cleavage of RNA substrates *in vitro* and *in vivo*. The compositions contain part of an active center, with the other part of the active center provided by the RNA substrate. The subunits of the active center region of the compositions are nucleotides and/or nucleotide analogues. The disclosed compositions also have flanking regions contributing to the formation of a specific hybridization with an RNA substrate. Preferred compositions form, in combination with an RNA substrate, a structure resembling a hammerhead structure. The active center of the disclosed compositions is characterized by the presence of I^{15.1} which allows cleavage of RNA substrates having C^{16.1}.

25
30

All naturally occurring hammerhead ribozymes have an A^{15.1}-U^{16.1} base pair. In addition, it is known that substrates for ribozymes based on the consensus hammerhead sequence strongly prefer a substrate that contains an N^{16.2}U^{16.1}H¹⁷ triplet in which H¹⁷ is not a guanosine (Koizumi *et al.*, *FEBS Lett.* 228, 228-230 (1988); Ruffner *et al.*, *Biochemistry* 29, 10695-10702 (1990); Perriman *et al.*, *Gene* 113, 157-163 (1992)). Many experiments have been done in an attempt to isolate ribozymes which are able to efficiently relieve the requirement of a U at position 16.1, however, attempts to find ribozymes which can cleave substrates having a base other than a U at position 16.1 have proven impossible (Perriman *et al.*, *Gene* 113, 157-163 (1992, Singh *et al.*, *Antisense and Nucleic Acid Drug Development* 6:165-168 (1996)).

However, examination of the recently published X-ray crystal structures (Pley *et al.*, *Nature* 372:68-74 (1994), Scott *et al.*, *Cell* 81:991-1002 (1995), and Scott *et al.*, *Science* 274:2065-2069 (1996)) led to the realization that the A^{15.1}-U^{16.1} interaction is a non-standard base pair with a single hydrogen bond between the exocyclic amine (N6) of the adenosine and the 4-oxo group of the uridine. Modeling studies (based on the crystal structure) then led to the discovery that the interaction of the wild-type A^{15.1}-U^{16.1} base pair can be spatially mimicked by replacement with an I^{15.1}-C^{16.1} base pair that adopts an isostructural orientation and which preserves the required contact of the 2-keto group of C^{16.1} with A⁶ of the uridine turn. In the model, the polarity of the stabilizing hydrogen bond between positions 15.1 and 16.1 is reversed in the I^{15.1}-C^{16.1} interaction, but the correct orientation of the bases around this bond is maintained.



It has been discovered that Gerlach type ribozyme analogues containing an inosine at position 15.1 readily cleave RNA substrates containing an N^{16.2}C^{16.1}H¹⁷ triplet. Based on this, disclosed are compositions, preferably synthetic oligomers, which induce cleavage of a nucleic acid target sequence containing the structure 5'-Z₃'-C^{16.1}-X¹⁷-S-Z₄-Z₁'-3' where S is capable of forming a stem and loop and Z₄ corresponds to part of an active center. It is preferred that X¹⁷ is not guanosine. The ability to induce

cleavage of substrates having $N^{16.2}C^{16.1}X^{17}$ triplets effectively doubles the number of targets available for cleavage using compositions of the type disclosed.


Compositions Inducing RNA Cleavage in a Substrate

Specifically disclosed is a composition that induces cleavage of an RNA substrate, where the composition includes a structure $5'-Z_1-Z_2-Z_3-3'$. Elements Z_1 and Z_3 are each oligomeric sequences which are made up of nucleotides, nucleotide analogues, or a combination of both, or are oligonucleotide analogues. The oligomeric sequences of elements Z_1 and Z_3 specifically interact with the RNA substrate, preferably by hybridization.

In these preferred compositions, element Z_2 has a structure of



Element Z_2 in these preferred compositions is made up of nucleotides, nucleotide analogues, or a combination of both. The nucleotides and nucleotide analogues in element Z_2 each have the structure



(I)

In structure (I) each B can be adenin-9-yl, cytosin-1-yl, guanin-9-yl, uracil-1-yl, uracil-5-yl, hypoxanthin-9-yl, thymin-1-yl, 5-methylcytosin-1-yl, 2,6-diaminopurin-9-yl, purin-9-yl, 7-deazaadenin-9-yl, 7-deazaguanin-9-yl, 5-propynylcytosin-1-yl, 5-propynyluracil-1-yl, isoguanin-9-yl, 2-aminopurin-9-yl, 6-methyluracil-1-yl, 4-thiouracil-1-yl, 2-pyrimidone-1-yl, quinazoline-2,4-dione-1-yl, xanthin-9-yl, N^2 -dimethylguanin-9-yl or a functional equivalent thereof;

Each V can be an O, S, NH, or CH_2 group.

Each W can be -H, -OH, -COOH, -CONH₂, -CONHR¹, -CONR¹R², -NH₂, -NHR¹, -NR¹R², -NHCOR¹, -SH, SR¹, -F, -ONH₂, -ONHR¹, -ONR¹R², -NHOH, -NHOR¹, -NR²OH, -NR²OR¹, substituted or unsubstituted C₁-C₁₀ straight chain or branched alkyl, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkenyl, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkynyl, substituted or unsubstituted C₁-C₁₀ straight chain or branched alkoxy, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkenyloxy, and substituted or unsubstituted C₂-C₁₀ straight chain or branched alkynyloxy. The substituents for W groups are independently halogen, cyano, amino, carboxy, ester, ether, carboxamide, hydroxy, or mercapto. R¹ and R² can be substituted or unsubstituted alkyl, alkenyl, or alkynyl groups, where the substituents are independently halogen, cyano, amino, carboxy, ester, ether, carboxamide, hydroxy, or mercapto.

D and E are residues which together form a phosphodiester or phosphorothioate diester bond between adjacent nucleosides or nucleoside analogues or together form an analogue of an internucleosidic bond.

B is hypoxanthin-9-yl, or a functional equivalent thereof, in X^{15.1}; B can be guanine-9-yl, hypoxanthin-9-yl or 7-deazaguanine-9-yl in X¹²; B can be adenine-9-yl, 2,6-diaminopurine-9-yl, purine-9-yl or 7-deazaadenine-9-yl in X¹³ and X¹⁴; and B can be adenine-9-yl, cytosine-1-yl, guanine-9-yl, uracil-1-yl, uracil-5-yl, hypoxanthin-9-yl, thymine-1-yl, 5-methylcytosine-1-yl, 2,6-diaminopurine-9-yl, purine-9-yl, 7-deazaadenine-9-yl, 7-deazaguanine-9-yl, 5-propynylcytosine-1-yl, 5-propynyluracil-1-yl, isoguanine-9-yl, 2-aminopurine-9-yl, 6-methyluracil-1-yl, 4-thiouracil-1-yl, 2-pyrimidone-1-yl, quinazoline-2,4-dione-1-yl, xanthine-9-yl, N²-dimethylguanine-9-yl or a functional equivalent thereof in X¹². B of X^{15.1} is preferably an analog of hypoxanthin-9-yl, preferably where no hydrogen bond can form between any group at the 2 position of the base and the 2-oxo group of C^{16.1}. Preferably, B is not guanine-9-yl in X^{15.1}.

B in X¹², X¹³, and X¹⁴ can also be a functionally equivalent nucleobase within the context of the catalytic core of a hammerhead ribozyme.

The disclosed compositions have significant advantages. For example, the disclosed compositions require only $4+N+M$ or $5+N+M$ monomeric units (for example, nucleotides) in which N and M are preferably numbers in the range of 5 to 10. Furthermore, the disclosed compositions can contain a significantly smaller number of natural ribonucleotides without loss of activity. Due to the reduced length and reduced number of ribonucleotides, the disclosed compositions are more conveniently and easily synthesized, and can be more stable *in vivo*, than Gerlach type ribozymes. The *in vivo* stability can be increased by a further reduction in the number of ribonucleotides.

Definitions

As used herein, oligomer refers to oligomeric molecules composed of subunits where the subunits can be of the same class (such as nucleotides) or a mixture of classes. It is preferred that the disclosed oligomers be oligomeric sequences. It is more preferred that the disclosed oligomers be oligomeric sequences. Oligomeric sequences are oligomeric molecules where each of the subunits includes a nucleobase (that is, the base portion of a nucleotide or nucleotide analogue) which can interact with other oligomeric sequences in a base-specific manner. The hybridization of nucleic acid strands is a preferred example of such base-specific interactions. Oligomeric sequences preferably are comprised of nucleotides, nucleotide analogues, or both, or are oligonucleotide analogues.

As used herein, nucleoside refers to adenosine, guanosine, cytidine, uridine, 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, or thymidine. A nucleoside analogue is a chemically modified form of nucleoside containing a chemical modification at any position on the base or sugar portion of the nucleoside. As used herein, the term nucleoside analogue encompasses, for example, both nucleoside analogues based on naturally occurring modified nucleosides, such as inosine and pseudouridine, and nucleoside analogues having other modifications, such as modifications at the 2' position of the sugar. As used herein, nucleotide refers to a phosphate derivative of nucleosides as described above, and a nucleotide analogue is a

phosphate derivative of nucleoside analogues as described above. The subunits of oligonucleotide analogues, such as peptide nucleic acids, are also considered to be nucleotide analogues.

As used herein, a ribonucleotide is a nucleotide having a 2' hydroxyl function. Analogously, a 2'-deoxyribonucleotide is a nucleotide having only 2' hydrogens. Thus, ribonucleotides and deoxyribonucleotides as used herein refer to naturally occurring nucleotides having nucleoside components adenosine, guanosine, cytidine, and uridine, or 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, and thymidine, respectively, without any chemical modification. Ribonucleosides, deoxyribonucleosides, ribonucleoside analogues and deoxyribonucleoside analogues are similarly defined except that they lack the phosphate group, or an analogue of the phosphate group, found in nucleotides and nucleotide analogues.

As used herein, oligonucleotide analogues are polymers of nucleic acid-like material with nucleic acid-like properties, such as sequence dependent hybridization, that contain at one or more positions, a modification away from a standard RNA or DNA nucleotide. A preferred example of an oligonucleotide analogue is peptide nucleic acid.

As used herein, base pair refers to a pair of nucleotides or nucleotide analogues which interact through one or more hydrogen bonds. The term base pair is not limited to interactions generally characterized as Watson-Crick base pairs, but includes non-canonical or sheared base pair interactions (Topal and Fresco, *Nature* 263:285 (1976); Lomant and Fresco, *Prog. Nucl. Acid Res. Mol. Biol.* 15:185 (1975)). Thus, nucleotides A^{15.1} and U^{16.1} form a base pair in hammerhead ribozymes (see Figure 1) but the base pair is non-canonical (see Figure 3).

The internucleosidic linkage between two nucleosides can be achieved by phosphodiester bonds or by modified phospho bonds such as by phosphorothioate groups or other bonds such as, for example, those described in U.S. Pat. No. 5,334,711.


Flanking Elements Z_1 and Z_3

The monomeric subunits of elements Z_1 and Z_3 which flank the active center (formed by element Z_2) are preferably nucleotides and/or nucleotide analogues. Elements Z_1 and Z_3 are designed so that they specifically interact, preferably by hybridization, with a given RNA substrate and, together with the element Z_2 , form a structure (preferably a structure resembling part of a hammerhead ribozyme) which induces specific cleavage of the RNA substrate.

The subunits of elements Z_1 and Z_3 can, on the one hand, be ribonucleotides. However, it is preferred that the number of ribonucleotides be as small as possible since the presence of ribonucleotides reduces the *in vivo* stability of the oligomers. Elements Z_1 and Z_3 (and also the active center Z_2) preferably do not contain any ribonucleotides at the positions containing pyrimidine nucleobases. Such positions preferably contain nucleotide analogues.

The use of a large number of deoxyribonucleotides in elements Z_1 and Z_3 is also less preferred since undesired interactions with proteins can occur or an unintended RNase H-sensitive DNA-RNA hybrid could form. Thus, elements Z_1 and Z_3 each preferably contain (1) no ribonucleotides, and (2) no sequences of more than 3 consecutive deoxyribonucleotides.

The subunits of elements Z_1 and Z_3 are preferably nucleotides, nucleotide analogues, or a combination. Preferably, the nucleotides and nucleotide analogues in elements Z_1 and Z_3 each have the structure



(I)

In structure (I) each B can be adenin-9-yl, cytosin-1-yl, guanin-9-yl, uracil-1-yl, uracil-5-yl, hypoxanthin-9-yl, thymine-1-yl, 5-methylcytosin-1-yl, 2,6-diaminopurin-9-yl, purin-9-yl, 7-deazaadenin-9-yl, 7-deazaguanin-9-yl, 5-propynylcytosin-1-yl, 5-propynyluracil-1-yl, isoguanin-9-yl, 2-aminopurin-9-yl, 6-methyluracil-1-yl, 4-thiouracil-1-yl, 2-pyrimidone-1-yl, quinazoline-2,4-dione-1-yl, xanthin-9-yl, N²-dimethylguanin-9-yl or a functional equivalent thereof;

Each V can be an O, S, NH, or CH₂ group.

Each W can be -H, -OH, -COOH, -CONH₂, -CONHR¹, -CONR¹R², -NH₂, -NHR¹, -NR¹R², -NHCOR¹, -SH, SR¹, -F, -ONH₂, -ONHR¹, -ONR¹R², -NHOH, -NHOR¹, -NR²OH, -NR²OR¹, substituted or unsubstituted C₁-C₁₀ straight chain or branched alkyl, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkenyl, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkynyl, substituted or unsubstituted C₁-C₁₀ straight chain or branched alkoxy, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkenyloxy, and substituted or unsubstituted C₂-C₁₀ straight chain or branched alkynyloxy. The substituents for W groups are independently halogen, cyano, amino, carboxy, ester, ether, carboxamide, hydroxy, or mercapto. R¹ and R² can be substituted or unsubstituted alkyl, alkenyl, or alkynyl groups, where the substituents are independently halogen, cyano, amino, carboxy, ester, ether, carboxamide, hydroxy, or mercapto.

D and E are residues which together form a phosphodiester or phosphorothioate diester bond between adjacent nucleosides or nucleoside analogues or together form an analogue of an internucleosidic bond.

For elements Z₁ and Z₃ having nucleotide and/or nucleotide analogues of structure (I), it is preferred that each W is substituted or unsubstituted C₁-C₁₀ straight chain or branched alkoxy, C₂-C₁₀ straight chain or branched alkenyloxy, or C₂-C₁₀ straight chain or branched alkynyloxy.


In addition, the flanking elements Z₁ and Z₃ can also contain nucleotide analogues such as peptide nucleic acids (also referred to as peptidic nucleic acids; see for example Nielsen *et al.*, *Science* 254:1497-1500 (1991), and Dueholm *et al.*, *J. Org. Chem.* 59:5767-5773 (1994)). In this case the

coupling of individual subunits can, for example, be achieved by acid amide bonds. Elements Z_1 and Z_3 , when based on peptide nucleic acids, can be coupled to element Z_2 , based on nucleotides or nucleotide analogues, using either suitable linkers (see, for example, Petersen *et al.*, *BioMed. Chem. Lett.* 5:1119-1121 (1995)) or direct coupling (Bergmann *et al.*, *Tetrahedron Lett.* 36:6823-6826 (1995)). Where elements Z_1 and Z_3 contain a combination of nucleotides (and/or nucleotide analogues) and peptide nucleic acid, similar linkages can be used to couple the different parts.

The subunits of the flanking elements Z_1 and Z_3 contain nucleobases or nucleobase analogues which can hybridize or interact with nucleobases that occur naturally in RNA molecules. The nucleobases are preferably selected from naturally occurring bases (that is, adenine, guanine, cytosine, thymine and uracil) as well as nucleobase analogues, such as 2,6-diaminopurine, hypoxanthine, 5-methylcytosine, pseudouracil, 5-propynyluracil, and 5-propynylcytosine, which enable a specific binding to the target RNA.

A strong and sequence-specific interaction (that is, a more stable hybrid between the RNA substrate and the oligomer) between the RNA substrate and elements Z_1 and Z_3 is preferred. For this purpose, it is preferred that the following nucleobase analogues be used in oligomeric sequences of elements Z_1 and Z_3 in place of the standard nucleobases: 2,6-diaminopurine instead of adenine; thymine or 5-propynyluracil instead of uracil; and 5-methylcytosine or 5-propynylcytosine instead of cytosine. 2-Amino-2'-O-alkyladenosines are also preferred (Lamm *et al.*, *Nucleic Acids Res.* 19:3193-3198 (1991)). Furthermore, aromatic systems can be linked to positions 4 and 5 of uracil to produce nucleobase analogues such as phenoxazine, which can improve the stability of the double-strand (Lin *et al.*, *J. Am. Chem. Soc.* 117:3873-3874 (1995)).

Preferred RNA substrates for cleavage using the disclosed compositions have the structure



where Z_1' and Z_3' interact with Z_1 and Z_3 , respectively, where $C^{16.1}$ is cytidine, and where X^{17} is adenosine, guanosine, cytidine, or uridine. S is an

RNA sequence capable of forming a hairpin structure with a length of preferably from 6 to 60 and more preferably of from 6 to 20 bases. Cleavage occurs 3' of X¹⁷. Preferably, X¹⁷ is adenosine, cytidine, or uridine, more preferably X¹⁷ is adenosine or cytidine, and most preferably X¹⁷ is adenosine.

5 Preferably, X^{16.2} (that is, the 3' nucleoside in element Z₃') is adenosine or guanosine. The target sites in substrates which can be cleaved using the disclosed compositions are distinct from target sites for hammerhead ribozymes since hammerhead ribozymes require a uridine in position 16.1 of the substrate.

10 Structure S is not required to have only contiguous base pairing within the hairpin. The hairpin must simply be stable enough to allow the correct positioning of the bases in Z₄ to effect cleavage of the substrate. The hairpin must be stable enough when bound to the oligomer to allow for the correct formation of the catalytic core of the complex. It is realized that the


15 more stable the stems created by Z₁:Z₁' and Z₃:Z₃' are, the less structural requirement that must be provided by the hairpin. 2'-O-allylated oligonucleotides have been shown to have much higher binding affinities for hybridizing to ribooligonucleotides than oligomers composed of only ribonucleic acid. This means that 2'-O-allylated oligomers can promote

20 formation of the correct oligomer:substrate structure even when the substrate structure is unformed in the absence of the oligomer.

It is preferred that structure S have at least two contiguous base pairs juxtaposed to X¹⁷ and the 5' most base of Z₄. It is more preferred that the stem have at least four contiguous base pairs juxtaposed to X¹⁷ and the 5'

25 most base of Z₄. It is most preferred that the stem have at least six contiguous base pairs juxtaposed to X¹⁷ and the 5' most base of Z₄.

Element Z₄ of the substrate has the structure



30 where X⁵ and X⁸ are both guanosine, X⁶ and X⁹ are both adenosine, X⁴ is uridine, X³ is cytidine, and X⁷ and X^{9^{\wedge}} are adenosine, guanosine, cytidine, or uridine. The disclosed composition, in combination with an

RNA substrate containing a structure of element Z_4 , can form a structure resembling a hammerhead as shown in Figure 2.

It is preferred that Z_1 interact with Z_1' in such a way as to stabilize the interactions between Z_2 and Z_4 . Although preferred, it is not required that element Z_1 be present in the disclosed compositions. In this case, it is preferred that element Z_1' (in the substrate) include a G at the 5' end (that is, at the junction of elements Z_4 and Z_1'). Taira and co-workers (Amontov and Taira, *J. Am. Chem. Soc.* 118:1624-1628 (1996)) have shown that the stacking energy gained from a guanosine juxtaposed to R^9 of a hammerhead-like ribozyme stabilizes the formation of a catalytic structure. Thus, it is preferred that the 5' nucleotide of Z_1' is G.

The cleavage motif $C^{16.1}-X^{17}-S-Z_4$ occurs only rarely (approximately one motif for every 5000 to 10,000 nucleotides). This, taken together with the individually selected recognition sequences, means that, statistically, a composition as disclosed should induce cleavage of only the selected target RNA within the entire human RNA pool. Only an unproductive binding but no cleavage occurs at other potential binding sites, since $C^{16.1}$, X^{17} , and elements S and Z_4 are required for cleavage. In addition, the disclosed compositions need not activate RNase H since they can be made with a low content of deoxyribonucleotides. This prevents induction of any unwanted non-specific cleavage.

Computer algorithms can be used to identify RNA substrates in sequence databases suitable for use with the disclosed compositions. An example of such an algorithm is (using the numbering according to Figure 2):

- i: find all C^3 UGANGA(N)R sequences in a given mRNA;
- ii: identify $N^{2.1}$ and find potential $N^{1.1}-N^{2.1}$ base pairs (in which $N^{1.1}$ must be part of an $N^{16.2}-C^{16.1}-H^{17}-N^{1.1}$ sequence) in a region positioned approximately 30 nucleotides from C^3 in the 3' direction;
- iii: calculate stem stabilities for stems which terminate at the above-mentioned $N^{1.1}-N^{2.1}$ base pairs;
- iv: sort according to stem stability.

A program based on these algorithms enables a very efficient search in databases or individual sequences. As a result, in addition to a suitable RNA target sequence, one obtains the sequence of the oligomer which is necessary to induce cleavage of this target sequence. In this connection it is
5 important to also take into consideration potential target sites containing incomplete base pairs in the region of the stem structure (that is, element S) since several incomplete base pairs (mismatches) can be tolerated in this section.

Preferred RNA substrates for cleavage using the disclosed
10 compositions are human cellular transcripts and transcripts of human or animal viruses as well as transcripts of bacteria and fungi that infect humans. Preferred RNA substrates are human dopamine D2 receptor mRNA, human brain cholecystokinin receptor mRNA, human serotonin 5-HT₃ receptor mRNA, human alpha-2-macroglobulin receptor RNA, human tyrosine kinase-
15 type receptor (HER2) mRNA, human interleukin 2 receptor beta chain mRNA, human MAD-3 mRNA, human bcl-1 mRNA, human bcl-2 mRNA, human cyclin F mRNA, human cyclin G1 mRNA, human bleomycin hydrolase mRNA, human acute myeloid leukemia 1 oncogene mRNA, human polycystic kidney disease 1 protein (PKD1) mRNA, transcripts of the bovine
20 viral diarrhea virus, transcripts of the foot and mouth disease virus 3D gene and transcripts of the Epstein-Barr virus.

Particularly preferred cleavage motifs are located at the following positions of the RNA substrates (the name of the respective sequence in the EMBL Nucleotide Sequence Database 49th or 50th Edition is given in
25 parentheses):

human dopamine D2 receptor mRNA (HSDRD2A) with N^{16.2} at position 2355 and a cleavage after the triplet UCU;

human brain cholecystokinin receptor mRNA (HSBRACHE) with N^{16.2} at position 1519 and a cleavage after the triplet ACA;

30 human serotonin 5-HT₃ receptor mRNA (HSS5HT3RA) with N^{16.2} at position 467 and a cleavage after the triplet ACA;

human alpha-2-macroglobulin receptor RNA (HS2MRLR08) with N^{16.2} at position 776 and a cleavage after the triplet GCC;

human tyrosine kinase-type receptor (HER2) mRNA (HSHER2A) with N^{16.2} at position 3330 and a cleavage after the triplet ACU;

5 human interleukin 2 receptor beta chain mRNA (HSIL2RBC) with N^{16.2} at position 937 and a cleavage after the triplet ACA;

human MAD-3 mRNA (HSMAD3A) with N^{16.2} at position 138 and a cleavage after the triplet GCC;

10 human bcl-1 mRNA (HSBCL1G) with N^{16.2} at position 777 and a cleavage after the triplet GCA;

human bcl-2 mRNA (HSBCL2A) with N^{16.2} at position 4152 and a cleavage after the triplet ACC;

human cyclin F mRNA (HSCYCLF) with N^{16.2} at position 378 and a cleavage after the triplet ACA;

15 human cyclin G1 mRNA (HSCYCGIR) with N^{16.2} at position 166 and a cleavage after the triplet GCC;

human bleomycin hydrolase mRNA (HSBLEO) with N^{16.2} at position 1352 and a cleavage after the triplet ACA;

20 human acute myeloid leukemia 1 oncogene mRNA (HSAML1) with N^{16.2} at position 883 and a cleavage after the triplet GCC;

human polycystic kidney disease 1 protein mRNA (HSPKD1A) with N^{16.2} at position 11354 and a cleavage after the triplet GCC;

transcripts of the bovine viral diarrhea virus (BV25053) with N^{16.2} at position 616 and cleavage after the triplet GCC;

25 transcripts of the foot and mouth disease virus 3D gene (FMDV3D) with N^{16.2} at position 1291 and a cleavage after the triplet GCA; and

transcripts of the Epstein-Barr virus (HEEBVT2R) with N^{16.2} at position 1647 and a cleavage after the triplet GCA.

30 Flanking elements Z₁ and Z₃ preferably contain, independently of each other, from 3 to 40, and more preferably from 5 to 10, nucleotides or nucleotide analogues. It is preferred that Z₁ and Z₁' interact to form a stem of at least three base pairs, and that Z₃ and Z₃' interact to form a stem of at

least three base pairs. It is more preferred that these stems are adjacent to Z_2 . It is most preferable that Z_1 and Z_1' interact to form a stem of more than three base pairs, and that Z_3 and Z_3' interact to form a stem of more than three base pairs.

5 A particularly preferred substrate is the RNA for the human serotonin 5-HT3 receptor. The cleavage site motif found in the substrate has the nucleotide sequence shown in SEQ ID NO:22. A chimeric oligomer that targets this site has the nucleotide sequence shown in SEQ ID NO:23. The cleavage site in this substrate, includes an $A^{16.2}C^{16.1}A^{17}$ triplet, a uridine at
10 position N^7 and two tandem G•U wobble pairs in stem I.

 Another particularly preferred example of a substrate is the human bcl-2 mRNA. The nucleotide sequence of the motif forming region of this substrate is shown in SEQ ID NO:24. The sequence of an oligomer designed to induce cleavage of the bcl-2 mRNA is shown in SEQ ID NO:25. The
15 substrate contains an ACC triplet, a guanosine at position N^7 and a G•A mismatch in stem I.

 Another particularly preferred example of an RNA substrate is the RNA encoding human polycystic kidney disease 1 protein. The nucleotide
20 sequence of the motif forming region of this substrate is shown in SEQ ID NO. 26. The nucleotide sequence of the chimeric oligomer designed to cleave this RNA is shown SEQ ID NO. 27. The substrate contains a GCC triplet and a guanosine at position N^7 .

 The RNA polymerase of foot and mouth disease virus is an RNA dependent polymerase. The RNA encoding this polymerase is another
25 particularly preferred substrate. The nucleotide sequence of the motif forming region of the substrate is shown in SEQ ID NO:28. The nucleotide sequence of a chimeric oligomer designed to target this substrate is shown in SEQ ID NO:29. The substrate, contains a GCA triplet and a cytidine at position N^7 .

30 The Epstein-Barr virus mRNA T2 of the 84 kb transcription unit is a further particularly preferred example of a substrate. The nucleotide sequence of the motif forming region of the substrate is shown in SEQ ID

NO:30. The nucleotide sequence of a chimeric oligomer is shown in SEQ ID

NO:31. The substrate, contains a GCA triplet and a uridine at position N⁷.

Catalytic Core

Elements Z₂ and Z₄ are considered to form the catalytic core of the
 5 combination of a disclosed composition and an RNA substrate (see Figure 2).
 Z₂ is preferably made up of nucleotide analogues. In element Z₂ it is
 preferred that each W (in structure (I)) is C₁-C₅ straight chain or branched
 alkyl, C₂-C₅ straight chain or branched alkenyl, C₂-C₅ straight chain or
 branched alkynyl, C₁-C₅ straight chain or branched alkoxy, C₂-C₅ straight
 10 chain or branched alkenyloxy, and C₂-C₅ straight chain or branched C₂-C₅
 alkynyloxy. It is also preferred that in X¹², W is NH₂, OH-substituted C₁-
 C₄ alkyl, OH-substituted C₂-C₄ alkenyl, OH-substituted C₁-C₄ alkoxy or OH-
 substituted C₂-C₄ alkenyloxy. It is more preferred that in X¹², W is NH₂,
 methoxy, 2-hydroxyethoxy, allyloxy or allyl. It is also preferred that in X¹²,
 15 W is -H or -OH. It is also preferred that in each X¹³ and X¹⁴, W is C₁-C₄
 alkyl, C₂-C₄ alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, OH-substituted C₁-C₄
 alkyl, OH-substituted C₂-C₄ alkenyl, OH-substituted C₁-C₄ alkoxy, or OH-
 substituted C₂-C₄ alkenyloxy. It is more preferred that in each X¹³ and X¹⁴,
 W is methoxy, 2-hydroxyethoxy or allyloxy.

20 The subunits in element Z₂ are preferably nucleotide analogues which
 can only hybridize weakly with ribonucleotides. Examples of such subunits
 are nucleotide analogues that contain a substituted or unsubstituted alkyl,
 alkenyl, alkynyl, alkoxy, alkenyloxy or alkynyloxy group, with preferably 1
 to 5 carbon atoms, at the 2' position of ribose. Preferred nucleobases which
 25 can be used in element Z₂ for this purpose are adenin-9-yl, purin-9-yl,
 guanin-9-yl and hypoxanthin-9-yl.

The following nucleotides and nucleotide analogues are preferred for
 element Z₂ (referring to components of structure (I)):

Position X¹²: B = guanin-9-yl, V = O, W = H; B = 7-deazaguanin-
 30 9-yl, V = O, W = OH; or B = guanin-9-yl, V = O, W = OH;

Position X¹³: B = adenin-9-yl, V = O, W = allyloxy; or B = adenin-9-yl, V = O, W = 2-hydroxyethoxy; B = purin-9-yl, V = O, W = allyloxy;

Position X¹⁴: B = adenin-9-yl, V = O, W = allyloxy; B = purin-9-yl, V = O, W = OH; or B = adenin-9-yl, V = O, W = 2-hydroxyethoxy; B = purin-9-yl, V = O, W = allyloxy;

Position X^{15.1}: B = hypoxanthin-9-yl or a functional equivalent thereof, V = O, W = OH.

Elements Z₂ and Z₄ interact in a way that allows for the formation of a catalytic structure. In preferred compositions Z₂ and Z₄ interact in a way that allows for the formation of a catalytic structure resembling a hammerhead catalytic structure. One way Z₂ and Z₄ can interact to form a catalytic structure is through the interaction of the nucleotides and/or nucleotide analogues making up Z₂ and the nucleotides making up Z₄. The disclosed compositions are able to induce cleavage of an RNA substrate independent of RNase H. That is, the disclosed compositions are able to induce cleavage of an RNA substrate without involving RNase H. Although the disclosed compositions may also be capable of promoting cleavage of RNA by RNase H, it is preferred that they do not.

The 3' end of the disclosed compositions can be protected against degradation by exonucleases by, for example, using a nucleotide analogue that is modified at the 3' position of the ribose sugar (for example, by including a substituted or unsubstituted alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl or alkynyloxy group as defined above). The disclosed compositions can also be stabilized against degradation at the 3' end by exonucleases by including a 3'-3'-linked dinucleotide structure (Ortigao *et al.*, *Antisense Research and Development* 2:129-146 (1992)) and/or two modified phospho bonds, such as two phosphorothioate bonds.

The disclosed compositions can also be linked to a prosthetic group in order to improve their cellular uptake and/or to enable a specific cellular localization. Examples of such prosthetic groups are polyamino acids (for example, polylysine), lipids, hormones or peptides. These prosthetic groups

are usually linked via the 3' or 5' end of the oligomer either directly or by means of suitable linkers (for example, linkers based on 6-aminohexanol or 6-mercaptohexanol). These linkers are commercially available and techniques suitable for linking prosthetic groups to the oligomer are known to a person skilled in the art.

Increasing the rate of hybridization can be important for the biological activity of the disclosed compositions since in this way it is possible to achieve a higher activity at low concentrations of the composition. This is important for short-lived RNA substrates or RNA substrates that occur less often. A substantial acceleration of the hybridization can be achieved by, for example, coupling positively charged peptides (containing, for example, several lysine residues) to the end of an oligonucleotide (Corey *J. Am. Chem. Soc.* 117:9373-9374 (1995)). The disclosed compositions can be simply modified in this manner using the linkers described above. Alternatively, the rate of hybridization can also be increased by incorporation of subunits which contain sperminyl residues (Schmid and Behr, *Tetrahedron Lett.* 36:1447-1450 (1995)). Such modifications of the disclosed compositions also improve the ability to bind to RNA substrates having secondary structures.

Synthesis of Oligomers

The disclosed compositions can be synthesized using any suitable method. Many synthesis methods are known. The following techniques are preferred for synthesis of the disclosed compositions. 2'-O-Allyl modified oligomers that contain residual purine ribonucleotides, and bearing a suitable 3'-terminus such as an inverted thymidine residue (Ortigao et al., *Antisense Research and Development* 2:129-146 (1992)) or two phosphorothioate linkages at the 3'-terminus to prevent eventual degradation by 3'-exonucleases, can be synthesized by solid phase β -cyanoethyl phosphoramidite chemistry (Sinha et al., *Nucleic Acids Res.* 12:4539-4557 (1984)) on any commercially available DNA/RNA synthesizer. A preferred method is the 2'-O-*tert*-butyldimethylsilyl (TBDMS) protection strategy for the ribonucleotides (Usman et al., *J. Am. Chem. Soc.* 109:7845-7854 (1987)), and all the required 3'-O-phosphoramidites are commercially

available. In addition, the use of aminomethylpolystyrene is preferred as the support material due to its advantageous properties (McCollum and Andrus *Tetrahedron Letters* 32:4069-4072 (1991)). Fluorescein can be added to the 5'-end of a substrate RNA during the synthesis by using commercially available fluorescein phosphoramidites. In general, a desired oligomer can be synthesized using a standard RNA cycle. Upon completion of the assembly, all base labile protecting groups are removed by an 8 hour treatment at 55°C with concentrated aqueous ammonia/ethanol (3:1 v/v) in a sealed vial. The ethanol suppresses premature removal of the 2'-O-TBDMS groups which would otherwise lead to appreciable strand cleavage at the resulting ribonucleotide positions under the basic conditions of the deprotection (Usman *et al.*, *J. Am. Chem. Soc.* 109:7845-7854 (1987)). After lyophilization the TBDMS protected oligomer is treated with a mixture of triethylamine trihydrofluoride/triethylamine/N-methylpyrrolidinone for 2 hours at 60°C to afford fast and efficient removal of the silyl protecting groups under neutral conditions (Wincott *et al.*, *Nucleic Acids Res.* 23:2677-2684 (1995)). The fully deprotected oligomer can then be precipitated with butanol according to the procedure of Cathala and Brunel (*Nucleic Acids Res.* 18:201 (1990)). Purification can be performed either by denaturing polyacrylamide gel electrophoresis or by a combination of ion-exchange HPLC (Sproat *et al.*, *Nucleosides and Nucleotides* 14:255-273 (1995)) and reversed phase HPLC. For use in cells, it is preferred that synthesized oligomers be converted to their sodium salts by precipitation with sodium perchlorate in acetone. Traces of residual salts are then preferably removed using small disposable gel filtration columns that are commercially available. As a final step it is preferred that the authenticity of the isolated oligomers is checked by matrix assisted laser desorption mass spectrometry (Pieles *et al.*, *Nucleic Acids Res.* 21:3191-3196 (1993)) and by nucleoside base composition analysis. In addition, a functional cleavage test with the oligomer and the corresponding chemically synthesized short oligoribonucleotide substrate is also preferred.

Cleavage of RNA Substrates

The disclosed compositions can have a very high *in vivo* activity since the RNA cleavage will be promoted by protein factors that are present in the nucleus or cytoplasm of the cell. Examples of such protein factors (which can increase the activity of hammerhead ribozymes) are, for example, the nucleocapsid protein NCp7 of HIV1 (Müller *et al.*, *J. Mol. Biol.* 242:422-429 (1994)) and the heterogeneous nuclear ribonucleoprotein A1 (Heidenreich *et al.*, *Nucleic Acids Res.* 23:2223-2228 (1995)). Thus, cleavage of long RNA transcripts can be efficiently induced within the cell by the disclosed compositions.

The disclosed compositions can be used in pharmaceutical compositions that contain one or several oligomers as the active substance, and, optionally, pharmaceutically acceptable auxiliary substances, additives and carriers. Such pharmaceutical compositions are suitable for the production of an agent to specifically inactivate the expression of genes in eukaryotes, prokaryotes and viruses, especially of human genes such as tumor genes or viral genes or RNA molecules in a cell. Further areas of application are the inactivation of the expression of plant genes or insect genes. Thus, the disclosed compositions can be used as drugs for humans and animals as well as a pesticide for plants.

A variety of methods are available for delivering the disclosed compositions to cells. For example, in general, the disclosed compositions can be incorporated within or on microparticles. As used herein, microparticles include liposomes, virosomes, microspheres and microcapsules formed of synthetic and/or natural polymers. Methods for making microcapsules and microspheres are known to those skilled in the art and include solvent evaporation, solvent casting, spray drying and solvent extension. Examples of useful polymers which can be incorporated into various microparticles include polysaccharides, polyanhydrides, polyorthoesters, polyhydroxides and proteins and peptides.

Liposomes can be produced by standard methods such as those reported by Kim *et al.*, *Biochim. Biophys. Acta*, 728:339-348 (1983); Liu *et*

al., *Biochim. Biophys. Acta*, 1104:95-101 (1992); and Lee *et al.*, *Biochim. Biophys. Acta.*, 1103:185-197 (1992); Wang *et al.*, *Biochem.*, 28:9508-9514 (1989)). Such methods have been used to deliver nucleic acid molecules to the nucleus and cytoplasm of cells of the MOLT-3 leukemia cell line (Thierry and Dritschilo, *Nucl. Acids Res.*, 20:5691-5698 (1992)). Alternatively, the disclosed compositions can be incorporated within microparticles, or bound to the outside of the microparticles, either ionically or covalently.

Cationic liposomes or microcapsules are microparticles that are particularly useful for delivering negatively charged compounds such as the disclosed compounds, which can bind ionically to the positively charged outer surface of these liposomes. Various cationic liposomes have previously been shown to be very effective at delivering nucleic acids or nucleic acid-protein complexes to cells both *in vitro* and *in vivo*, as reported by Felgner *et al.*, *Proc. Natl. Acad. Sci. USA*, 84:7413-7417 (1987); Felgner, *Advanced Drug Delivery Reviews*, 5:163-187 (1990); Clarenc *et al.*, *Anti-Cancer Drug Design*, 8:81-94 (1993). Cationic liposomes or microcapsules can be prepared using mixtures including one or more lipids containing a cationic side group in a sufficient quantity such that the liposomes or microcapsules formed from the mixture possess a net positive charge which will ionically bind negatively charged compounds. Examples of positively charged lipids that may be used to produce cationic liposomes include the aminolipid dioleoyl phosphatidyl ethanolamine (PE), which possesses a positively charged primary amino head group; phosphatidylcholine (PC), which possess positively charged head groups that are not primary amines; and N[1-(2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium ("DOTMA," see Felgner *et al.*, *Proc. Natl. Acad. Sci. USA*, 84:7413-7417 (1987); Felgner *et al.*, *Nature*, 337:387-388 (1989); Felgner, *Advanced Drug Delivery Reviews*, 5:163-187 (1990)).

A preferred form of microparticle for delivery of the disclosed compositions are heme-bearing microparticles. In these microparticles, heme is intercalated into or covalently conjugated to the outer surface of the microparticles. Heme-bearing microparticles offer an advantage in that since

they are preferentially bound and taken up by cells that express the heme receptor, such as hepatocytes, the amount of drug required for an effective dose is significantly reduced. Such targeted delivery may also reduce systemic side effects that can arise from using relatively high drug concentrations in non-targeted delivery methods. Preferred lipids for forming heme-bearing microparticles are 1,2-dioleoyloxy-3-(trimethylammonium) propane (DOTAP) and dioleoyl phosphatidyl ethanolamine (DOPE). The production and use of heme-bearing microparticles are described in PCT application WO 95/27480 by Innovir.

The disclosed compositions can also be encapsulated by or coated on cationic liposomes which can be injected intravenously into a mammal. This system has been used to introduce DNA into the cells of multiple tissues of adult mice, including endothelium and bone marrow, where hematopoietic cells reside (see, for example, Zhu *et al.*, *Science*, 261:209-211 (1993)).

Liposomes containing the disclosed compositions can be administered systemically, for example, by intravenous or intraperitoneal administration, in an amount effective for delivery of the disclosed compositions to targeted cells. Other possible routes include trans-dermal or oral, when used in conjunction with appropriate microparticles. Generally, the total amount of the liposome-associated oligomer administered to an individual will be less than the amount of the unassociated oligomer that must be administered for the same desired or intended effect.

Compositions including various polymers such as the polylactic acid and polyglycolic acid copolymers, polyethylene, and polyorthoesters and the disclosed compositions can be delivered locally to the appropriate cells by using a catheter or syringe. Other means of delivering such compositions locally to cells include using infusion pumps (for example, from Alza Corporation, Palo Alto, California) or incorporating the compositions into polymeric implants (see, for example, Johnson and Lloyd-Jones, eds., *Drug Delivery Systems* (Chichester, England: Ellis Horwood Ltd., 1987), which can effect a sustained release of the therapeutic compositions to the immediate area of the implant.

For therapeutic applications the active substance is preferably administered at a concentration of 0.01 to 10,000 $\mu\text{g/kg}$ body weight, more preferably of 0.1 to 1000 $\mu\text{g/kg}$ body weight. The administration can, for example, be carried out by injection, inhalation (for example as an aerosol),
5 as a spray, orally (for example as tablets, capsules, coated tablets etc.), topically or rectally (for example as suppositories).

The disclosed compositions can be used in a method for the specific inactivation of the expression of genes in which an active concentration of the composition is taken up into a cell so that the composition induces specific
10 cleavage of a predetermined RNA molecule which is present in the cell, the cleavage preferably occurring catalytically. Similar compositions, which are described in U.S. Patent No. 5,334,711, have been used successfully in mice to inactivate a gene (Lyngstadaas *et al.*, *EMBO J.* 14:5224-5229 (1995)). This process can be carried out *in vitro* on cell cultures as well as *in vivo* on
15 living organisms (prokaryotes or eukaryotes such as humans, animals or plants).

The disclosed compositions can also be used as RNA restriction enzymes to induce cleavage of RNA molecules (in, for example, cell free *in vitro* reactions). The disclosed compositions can also be used in a reagent kit
20 for the restriction cleavage of RNA molecules which contains, for example, an oligomer and suitable buffer substances. In this case the oligomer and the buffer substances can be present in the form of solutions, suspensions or solids such as powders or lyophilisates. The reagents can be present together, separated from one another or optionally also on a suitable carrier.
25 The disclosed compositions can also be used as a diagnostic agent or to identify the function of unknown genes.

The present invention will be further understood by reference to the following non-limiting examples.

Examples

30 The following examples demonstrate that compositions having motifs forming structures resembling hammerheads but which include $\text{I}^{15.1}$ and $\text{C}^{16.1}$ can result in specific cleavage of an RNA molecule. Although the examples

involve the use of oligomers having RNA cleaving activity and including motifs corresponding to both elements Z_2 and Z_4 (the oligomers in the examples are thus analogous to a Gerlach type ribozyme), the activities are indicative of the cleavage inducing activity of the disclosed compositions.

- 5 **Example 1: Cleavage reactions which indicate that an inosine substitution at position 15.1 can effectively cleave $N^{16.2}C^{16.1}H^{17}$.**

10 A set of 12 substrates was synthesized which covered each permutation of the $N^{16.2}C^{16.1}H^{17}$ motif where H^{17} is not guanosine. The oligomers and the corresponding substrates used in the cleavage assays are shown in Table 1. Each of the substrates was labeled with fluorescein at the 5' end and an inverted thymidine cap was used on the 3'-end. A set of four catalytic oligomers was synthesized, providing an appropriately matched catalytic oligomer for each of the substrates. Each of these catalytic
15 oligomers had an inosine at position 15.1. The catalytic oligomers were similar to those described in U.S. Patent No. 5,334,711 except for the substitution of I for A at position 15.1. The catalytic oligomers includes, in a single molecule, the equivalent of elements Z_4 , Z_1' , Z_1 , Z_2 , and Z_3 in the compositions and RNA substrates as described above. A control substrate
20 and catalytic oligomer were also synthesized in which there was a U at position 16.1 of the substrate and an A at position 15.1 of the catalytic oligomer.

Table 1

$N^{16.2}N^{16.1}H^{17}$			
Triplet	Substrate sequence		
5	ACC	FI-GAAUACCGGUCGC*T	(SEQ ID NO:4)
	ACA	FI-GAAUACAGGUCGC*T	(SEQ ID NO:5)
	ACU	FI-GAAUACUGGUCGC*T	(SEQ ID NO:6)
	GCC	FI-GAAUGCCGGUCGC*T	(SEQ ID NO:7)
	GCA	FI-GAAUGCAGGUCGC*T	(SEQ ID NO:8)
	GCU	FI-GAAUGCUGGUCGC*T	(SEQ ID NO:9)
10	CCC	FI-GAAUCCCGGUCGC*T	(SEQ ID NO:10)
	CCA	FI-GAAUCCAGGUCGC*T	(SEQ ID NO:11)
	CCU	FI-GAAUCCUGGUCGC*T	(SEQ ID NO:12)
15	UCC	FI-GAAUCCGGUCGC*T	(SEQ ID NO:13)
	UCA	FI-GAAUUCAGGUCGC*T	(SEQ ID NO:14)
	UCU	FI-GAAUUCUGGUCGC*T	(SEQ ID NO:15)
	GUC	FI-GAAUGUCGGUCGC*T	(SEQ ID NO:16)
Targeted triplet	Catalytic oligomer sequence		
20	ACH	gcgacccuGAuGaggccgugaggccGaaIuauc*T	(SEQ ID NO:17)
	GCH	gcgacccuGAuGaggccgugaggccGaaIcauc*T	(SEQ ID NO:18)
	CCH	gcgacccuGAuGaggccgugaggccGaaIgauuc*T	(SEQ ID NO:19)
	UCH	gcgacccuGAuGaggccgugaggccGaaIaauc*T	(SEQ ID NO:20)
	GUC	gcgacccuGAuGaggccgugaggccGaaAcauc*T	(SEQ ID NO:21)
25	Fl = Fluorescein label		
	*T = 3'-3' inverted thymidine		
	A, C, G, I, U = ribonucleotides (I is inosine)		
	a, c, g, u = 2'-O-allyl-ribonucleotides		

The above substrates and catalytic oligomers were used in cleavage reactions to determine the ability of an inosine at position 15.1 to overcome the requirement of a U at position 16.1 for cleavage. All of the reactions were performed using the following protocol. The reactions were typically done in 100 μ l and they contained distilled, autoclaved H₂O, 10 mM MgCl₂, 10 mM Tris-HCl pH 7.4, 5 μ M ribozyme, and 0.25 μ M substrate. The

catalytic oligomer, substrate, and buffer were added together and heated to 95°C for 5 minutes. After cooling to room temperature over 5 minutes the reactions were brought to 10 mM MgCl₂, mixed, and placed at 37°C. 10 μ L aliquots were removed at specific time intervals (10, 30, 60, and 120 minutes) and added to 3 μ L of loading buffer (95% formamide, 100 mM EDTA pH 8.0, 0.05% bromophenol blue) to quench the reaction. Samples were analyzed by 20% polyacrylamide gel electrophoresis. Gels were analyzed on a Molecular Dynamics Fluorescence Imager. The results of cleavage reactions of this type, using the substrates and catalytic oligomers shown in Table 1, are shown in Table 2.

Table 2

	N ^{16.2} Triplet	N ^{16.1} H ¹⁷	After mixing	10	30	60	120
	I ^{15.1} U ^{15.2} Catalytic oligomer						
15	ACC		4.4	28.2	58.1	91.5	91.5
	ACA		7.7	71.8	84.7	93.1	94.8
	ACU		1.8			58.7	70.5
	I ^{15.1} C ^{15.2} Catalytic oligomer						
20	GCC		1.62	39.6	59.9	82.0	87.0
	GCA		13.7	65.3	78.7	89.7	93.1
	GCU		--			64.3	74.8
	I ^{15.1} G ^{15.2} Catalytic oligomer						
25	CCC		--			34.33	45.38
	CCA		1.1	18.8	45.5	70.8	80.63
	CCU		2.0			28.4	36.7
	I ^{15.1} A ^{15.2} Catalytic oligomer						
	UCC		6.8			57.0	64.7
	UCA		1.6			39.6	60.8
	UCU		3.3			41.1	53.1
30	A ^{15.1} C ^{15.2} Catalytic oligomer						
	GUC		1.6	38.5	66.5	93.5	

The numbers represent the percentage of substrate cleaved at the indicated time point (which were at 0, 10, 30, 60, and 120 minutes after starting the reaction). The results indicate that substrates with a C at position 16.1 are able to be cleaved by catalytic oligomers containing an I at position 15.1. While there are differences between the various substrates at the 120 minute time point, the data show that a substrate with a C at position 16.1 in conjunction with a catalytic oligomer with an I at position 15.1 is able to effectively cleave in all backgrounds, indicating that the substitution of an I at position 15.1 does in fact allow for the cleavage of any appropriate substrate containing a N^{16.2}C^{16.1}H¹⁷ site.

Initial rates of cleavage of the twelve substrates having C^{16.1}, and the control substrate having U^{16.1}, by the corresponding catalytic oligomers (all shown in Table 1) were determined using single turnover kinetics. Single turnover kinetics were assessed by mixing 2.5 μ l of a 100 μ M ribozyme solution, 2.5 μ l of a 10 μ M solution of 5' fluorescein labeled substrate, and 10 μ l of a 100 mM Tris-HCl pH 7.4 solution. The mixture was diluted to a final volume of 90 μ l, heated to 95°C for 5 minutes, and cooled to 37°C. The reaction was started by adding 10 μ l of a 100 mM MgCl₂ solution. The final concentrations of the reaction components were 250 nM substrate, 2.5 μ mol ribozyme, and 10 mM MgCl₂. Ten microliter samples were removed at various times and mixed with 10 μ l of a 100 mM EDTA, bromphenol blue solution to stop the reaction. Cleavage products were separated from unreacted substrate by PAGE and were quantitated on a Molecular Dynamics Fluorescence Imager.

The data, measured in fraction of substrate cleaved versus time, were fitted to the equation:

$$\text{frac}[P] = H_0(1 - e^{-k_2 t})/S_0$$

as described by Jankowsky and Schwenzer, *Nucl. Acids Res.* 24:433 (1996).

The calculated values of k_2 for the various ribozymes are shown in Table 3.

Table 3

 $N^{16.2}N^{16.1}H^{17}$

Triplet

gcgacccuGAuGaggccgugaggccGaaIuauc*T (SEQ ID NO:17)		
5	k_2 (min ⁻¹)	Substrate sequence
ACC	0.07	FI-GAAUACCGGUCGC*T (SEQ ID NO:4)
ACA	0.36	FI-GAAUACAGGUCGC*T (SEQ ID NO:5)
ACU	0.026	FI-GAAUACUGGUCGC*T (SEQ ID NO:6)
gcgacccuGAuGaggccgugaggccGaaIcauc*T (SEQ ID NO:18)		
10	k_2 (min ⁻¹)	Substrate sequence
GCC	0.12	FI-GAAUGCCGGUCGC*T (SEQ ID NO:7)
GCA	0.48	FI-GAAUGCAGGUCGC*T (SEQ ID NO:8)
GCU	0.05	FI-GAAUGCUGGUCGC*T (SEQ ID NO:9)
gcgacccuGAuGaggccgugaggccGaaIgauuc*T (SEQ ID NO:19)		
15	k_2 (min ⁻¹)	Substrate sequence
CCC	<0.01	FI-GAAUCCCGGUCGC*T (SEQ ID NO:10)
CCA	0.04	FI-GAAUCCAGGUCGC*T (SEQ ID NO:11)
CCU	<0.01	FI-GAAUCCUGGUCGC*T (SEQ ID NO:12)
gcgacccuGAuGaggccgugaggccGaaIaauc*T (SEQ ID NO:20)		
20	k_2 (min ⁻¹)	Substrate sequence
UCC	<0.01	FI-GAAUCCGGUCGC*T (SEQ ID NO:13)
UCA	<0.01	FI-GAAUUCAGGUCGC*T (SEQ ID NO:14)
UCU	<0.01	FI-GAAUUCUGGUCGC*T (SEQ ID NO:15)
gcgacccuGAuGaggccgugaggccGaaAcauc*T (SEQ ID NO:21)		
25	k_2 (min ⁻¹)	Substrate sequence
GUC	0.13	FI-GAAUGUCGGUCGC*T (SEQ ID NO:16)

FI = Fluorescein label

*T = 3'-3' inverted thymidine

A, C, G, I, U = ribonucleotides (I is inosine)

a, c, g, u = 2'-O-allyl-ribonucleotides

30

The results show that substrates with $A^{16.2}C^{16.1}H^{17}$ and $G^{16.2}C^{16.1}H^{17}$ triplets are cleaved at a high rate. Comparison to the control catalytic oligomer having an A at position 15.1 (to cleave a substrate with a

G^{16.2}U^{16.1}C¹⁷ triplet) shows that substrates with A^{16.2}C^{16.1}A¹⁷ and G^{16.2}C^{16.1}A¹⁷ triplets (to be cleaved by a catalytic oligomer with an I at position 15.1) have an initial rate of cleavage that is higher than the corresponding control reactions involving reactants with a standard A^{15.1}-U^{16.1} base pair.

5 **Example 2: Cleavage of a human serotonin 5-HT3 receptor mRNA substrate**

10 A human serotonin 5-HT3 receptor mRNA substrate having the nucleotide sequence shown in SEQ ID NO:22 and a chimeric oligomer having the nucleotide sequence shown in SEQ ID NO:23 were produced by solid phase chemical synthesis (see Figure 4A). Regions Z₁ and Z₃ of the chimeric oligomer are composed of nucleotide analogue building blocks which are modified with an allyloxy group at the 2' position. Positions X¹³ and X¹⁴ are 2'-allyloxy-2'-deoxyadenosines.

15 Single-turnover kinetic reactions were set up as follows. 2.5 µl of a 100 µM chimeric oligomer stock solution was mixed with 2.5 µl of a 10 µM solution of 5'-fluorescein labelled human serotonin 5-HT3 receptor RNA substrate which was added to 10 µl of 100 mM Tris HCl buffer pH 7.4 and 90 µl of autoclaved water. This solution was heated at 95°C for two minutes and allowed to cool slowly to 37°C. The reaction was started by the addition of 10 µl of 100 mM MgCl₂ and incubated at 37°C. The final reaction conditions were: 250 nM substrate, 2.5 µM chimeric oligomer and 10 mM MgCl₂. 10 µl aliquots were withdrawn after 1, 2, 4, 6, 8, 10, 20, 60 and 90 minute intervals and quenched by addition of 3 µl of 100 mM Na₂EDTA/95% formamide/0.05% bromophenol blue stop mix. The time zero aliquot was taken from the reaction mixture after the heating/cooling cycle prior to the addition of MgCl₂. Cleavage products were separated from unreacted substrate for each time point by electrophoresis in a 20% polyacrylamide/1.5% bisacrylamide/7 M urea gel (14 x 16 cm) using Tris borate buffer, pH 8.0 containing 2 mM EDTA. The fluorescent bands were quantitated on a Molecular Dynamics FluorImager using version 4.2 of the Molecular Dynamics Image Quant software.

20

25

30

The results illustrated in Figure 4A are displayed in the form of a graph of fraction product versus time. The data were analyzed as in Example 1. The rate constant $k_2 = 0.18 \text{ min}^{-1}$. Furthermore, 75% of the target substrate is cleaved which indicates that the substrate is likely efficiently binding the substrate.

This example indicates that chimeric oligomers like those described in the invention are capable of targeting RNA, and together with this RNA, these oligomers can affect the cleavage of the target RNA. This indicates that the two tandem G•U wobble pairs in stem I do not prevent the oligomer from functioning.

Example 3: Cleavage of a human bcl-2 mRNA substrate

A human bcl-2 mRNA substrate having the nucleotide sequence shown in SEQ ID NO:24 and a cleavage inducing chimeric oligomer having the nucleotide sequence shown in SEQ ID NO:25 were synthesized using solid phase chemistry (see Figure 5A). Regions Z_1 and Z_3 of the chimeric oligomer are composed of nucleotide analogue building blocks which are modified with an allyloxy group at the 2'-C atom of the ribose. The region Z_2 consists of a riboguanosine at position X^{12} , a riboinosine at position $Z^{15,1}$ and 2'-allyloxy-2'-deoxyadenosine at positions X^{13} and X^{14} .

The cleavage reaction was performed as in Example 2, except time points were not taken past 20 minutes. The results of this example are shown in Figure 5A. The data were analyzed as in Example 1. The estimated rate constant $k_2 = 0.56 \text{ min}^{-1}$. This indicates that a G•A mismatch in stem I does not prevent activity. This example indicates that chimeric oligomers like those described in the invention are capable of targeting RNA, and together with this RNA, these oligomers can affect the cleavage of the target RNA.

Example 4: Cleavage of a human polycystic kidney disease 1 protein mRNA substrate

A human polycystic kidney disease 1 protein mRNA substrate having the nucleotide sequence shown in SEQ ID NO:26 and a cleavage inducing chimeric oligomer having the nucleotide sequence shown in SEQ ID NO:27

were synthesized using solid phase chemistry (see Figure 6A). Regions Z_1 and Z_3 of the chimeric oligomer are composed of nucleotide analogue building blocks which are modified with an allyloxy group at the 2'-C atom of the ribose. The region Z_2 consists of a riboguanosine at position X^{12} , a riboinosine at position $X^{15.1}$ and 2'-allyloxy-2'-deoxyadenosine at positions X^{13} and X^{14} . The cleavage reaction was performed as in Example 2, except that only time points up to 20 minutes were taken, and the graph showing fraction product versus time is shown in Figure 6A. The data were analyzed as in Example 1. The estimated rate constant $k_2 = 0.21 \text{ min}^{-1}$.

Example 5: Cleavage of a substrate derived from the RNA of the RNA-dependent RNA polymerase of foot and mouth disease virus

A substrate derived from the RNA of the RNA-dependent RNA polymerase of foot and mouth disease virus having the nucleotide sequence shown in SEQ ID NO:28 and a cleavage inducing chimeric oligomer having the nucleotide sequence shown in SEQ ID NO:29 were synthesized using solid phase chemistry (see Figure 7A). Regions Z_1 and Z_3 of the chimeric oligomer are composed of nucleotide analogue building blocks which are modified with an allyloxy group at the 2'-C atom of the ribose. The region Z_2 consists of a riboguanosine at position X^{12} , a riboinosine at position $X^{15.1}$ and 2'-allyloxy-2'-deoxyadenosine at positions X^{13} and X^{14} .

The cleavage reaction was performed as in Example 2, and the graph showing fraction product versus time is shown in Figure 7A. The data were analyzed as in Example 1. The cleavage rate is extremely fast with an estimated rate constant $k_2 = 1.33 \text{ min}^{-1}$. Furthermore, 80% of the substrate is cleaved indicating that the oligomer is most likely capable of interacting well with the substrate.

Example 6: Cleavage of a substrate derived from the Epstein-Barr virus mRNA T2 of 84 the kb transcription unit

A substrate derived from the Epstein-Barr virus mRNA T2 of 84 kb transcription unit having the nucleotide sequence shown in SEQ ID NO:30 and a cleavage inducing chimeric oligomer having the nucleotide sequence shown in SEQ ID NO:31 were synthesized in an analogous manner to that

described in example 2 (see Figure 8A). Regions Z_1 and Z_3 of the chimeric oligomer are composed of nucleotide analogue building blocks which are modified with an allyloxy group at the 2'-C atom of the ribose. The region Z_2 consists of a riboguanosine at position X^{12} , a riboinosine at position $X^{15.1}$ and 2'-allyloxy-2'-deoxyadenosine at positions X^{13} and X^{14} . The cleavage reaction was performed as in Example 2, and the graph showing fraction product versus time is shown in Figure 8A. The data were analyzed as in Example 1. The cleavage rate is extremely fast with an estimated rate constant $k_2 = 1.60 \text{ min}^{-1}$. Furthermore, 80% of the substrate is cleaved indicating that the oligomer is most likely capable of interacting well with the substrate.

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANT: Innovir Laboratories, Inc.
 - (ii) TITLE OF INVENTION: Compositions Inducing Cleavage of RNA Motifs
 - (iii) NUMBER OF SEQUENCES: 31
 - (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Patrea L. Pabst
 - (B) STREET: 2800 One Atlantic Center
1201 West Peachtree Street
 - (C) CITY: Atlanta
 - (D) STATE: GA
 - (E) COUNTRY: USA
 - (F) ZIP: 30309-3450
 - (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
 - (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
 - (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Pabst, Patrea L.
 - (B) REGISTRATION NUMBER: 31,284
 - (C) REFERENCE/DOCKET NUMBER: ILI 124
 - (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (404)-873-8794
 - (B) TELEFAX: (404)-873-8795

- (2) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 57 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: circular
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

NNNNNNNNNN NNNNNNCUGA NGANRNNNNNN NNNNNNNNYNG AARNNNNNNNN NNNNNNUH

57

- (2) INFORMATION FOR SEQ ID NO: 2:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

NNNNYNGAAN NNNN

14

- (2) INFORMATION FOR SEQ ID NO: 3:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

NNNNCHNNNN NNNNNNNNNNN NNCUGANGAN RNNNN

35

- (2) INFORMATION FOR SEQ ID NO: 4:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
GAAUACCGGU CGCT 14
- (2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
GAAUACAGGU CGCT 14
- (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
GAAUACUGGU CGCT 14
- (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
GAAUGCCGGU CGCT 14
- (2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
GAAUGCAGGU CGCT 14
- (2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
GAAUGCUGGU CGCT 14
- (2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
GAAUCCCGGU CGCT 14
- (2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
GAAUCCAGGU CGCT 14

(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
GAAUCCUGGU CGCT 14

(2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
GAAUCCGGU CGCT 14

(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
GAAUUCAGGU CGCT 14

(2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
GAAUUCUGGU CGCT 14

(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
GAAUGUCGGU CGCT 14

(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
GCGACCCUGA UGAGGCCGUG AGGCCGAANU AUUCT 35

- (2) INFORMATION FOR SEQ ID NO: 18:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
GCGACCCUGA UGAGGCCGUG AGGCCGAANC AUUCT 35
- (2) INFORMATION FOR SEQ ID NO: 19:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:
GCGACCCUGA UGAGGCCGUG AGGCCGAANG AUUCT 35
- (2) INFORMATION FOR SEQ ID NO: 20:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
GCGACCCUGA UGAGGCCGUG AGGCCGAANA AUUCT 35
- (2) INFORMATION FOR SEQ ID NO: 21:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
GCGACCCUGA UGAGGCCGUG AGGCCGAAAC AUUCT 35
- (2) INFORMATION FOR SEQ ID NO: 22:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 44 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
CCACCUACAU CUGGUACCGG CAGUACUGGA CUGAUGAGUU UCUC 44
- (2) INFORMATION FOR SEQ ID NO: 23:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
GAGAAACGAA NUAGGUGGT 19
- (2) INFORMATION FOR SEQ ID NO: 24:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 36 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
GAAAAACCUG GAUGUCACUG GCCACUGAGG AGCUUU 36
- (2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
ACAAAGCGAA NUUUUUCT 18
- (2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
UCCUGGCCAU CACGCGGUCU GAGGAGCUCU GG 32
- (2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
CCAGAGCGAA NCCAGGAT 18
- (2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
GGACUCGCAG UCCACUCUGG ACCUGACGAG UACCGG 36
- (2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
CCGGUACGAA NCGAGUCCT 19
- (2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
CGUCUGCACA GGUUGCUGCU GAUGAGAGCG GG 32


- (2) INFORMATION FOR SEQ ID NO: 31:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

CCCGCUCGAA NCAGACGT

18



Claims

1. A composition that induces cleavage of an RNA substrate, the composition comprising:




wherein Z_1 and Z_3 are oligomeric sequences which (1) are comprised of nucleotides, nucleotide analogues, or both, or (2) are oligonucleotide analogues, wherein the oligomeric sequences specifically interact with the RNA substrate by hybridization,

wherein Z_2 consists of



wherein Z_2 is comprised of nucleotides, nucleotide analogues, or both, wherein the nucleotides and nucleotide analogues each have the structure



wherein each B is independently adenin-9-yl, cytosin-1-yl, guanin-9-yl, uracil-1-yl, uracil-5-yl, hypoxanthin-9-yl, thymine-1-yl, 5-methylcytosin-1-yl, 2,6-diaminopurin-9-yl, purin-9-yl, 7-deazaadenin-9-yl, 7-deazaguanin-9-yl, 5-propynylcytosin-1-yl, 5-propynyluracil-1-yl, isoguanin-9-yl, 2-aminopurin-9-yl, 6-methyluracil-1-yl, 4-thiouracil-1-yl, 2-pyrimidone-1-yl, quinazoline-2,4-dione-1-yl, xanthin-9-yl, N²-dimethylguanin-9-yl or a functional equivalent thereof,

wherein each V is independently an O, S, NH, or CH₂ group,

wherein each W is independently selected from the group consisting of -H, -OH, -COOH, -CONH₂, -CONHR¹, -CONR¹R², -NH₂, -NHR¹, -NR¹R², -NHCOR¹, -SH, SR¹, -F, -ONH₂, -ONHR¹, -ONR¹R², -NHOH, -NHOR¹, -

NR²OH, -NR²OR¹, substituted or unsubstituted C₁-C₁₀ straight chain or branched alkyl, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkenyl, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkynyl, substituted or unsubstituted C₁-C₁₀ straight chain or branched alkoxy, substituted or unsubstituted C₂-C₁₀ straight chain or branched alkenyloxy, and substituted or unsubstituted C₂-C₁₀ straight chain or branched alkynyloxy, wherein the substituents are independently halogen, cyano, amino, carboxy, ester, ether, carboxamide, hydroxy, or mercapto, wherein R¹ and R² are, independently, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups, where the substituents are independently halogen, cyano, amino, carboxy, ester, ether, carboxamide, hydroxy, or mercapto,

wherein D and E are residues which together form a phosphodiester or phosphorothioate diester bond between adjacent nucleosides or nucleoside analogues or together form an analogue of an internucleosidic bond,

wherein in X^{15.1}, B is hypoxanthin-9-yl or a functional equivalent thereof,

wherein in X¹², B is independently guanine-9-yl, hypoxanthin-9-yl or 7-deazaguanine-9-yl;

wherein in X¹³ and X¹⁴, B is independently adenine-9-yl, 2,6-diaminopurine-9-yl, purine-9-yl or 7-deazaadenine-9-yl;

wherein in X¹², B is independently adenine-9-yl, cytosine-1-yl, guanine-9-yl, uracil-1-yl, uracil-5-yl, hypoxanthin-9-yl, thymine-1-yl, 5-methylcytosine-1-yl, 2,6-diaminopurine-9-yl, purine-9-yl, 7-deazaadenine-9-yl, 7-deazaguanine-9-yl, 5-propynylcytosine-1-yl, 5-propynyluracil-1-yl, isoguanine-9-yl, 2-aminopurine-9-yl, 6-methyluracil-1-yl, 4-thiouracil-1-yl, 2-pyrimidone-1-yl, quinazoline-2,4-dione-1-yl, xanthine-9-yl, N²-dimethylguanine-9-yl or a functional equivalent thereof.

2. The composition of claim 1 wherein the RNA substrate comprises 5'-Z₃'-C^{16.1}-X¹⁷-S-Z₄-Z₁'-3',

wherein Z₁' and Z₃' interact with Z₁ and Z₃, wherein C^{16.1} is cytidine, wherein X¹⁷ is adenosine, cytidine, or uridine, wherein S comprises a sequence capable of forming a hairpin structure,

wherein cleavage occurs 3' of X¹⁷,

wherein Z₄ consists of

5'-X³X⁴X⁵X⁶X⁷X⁸X⁹-3', or


5'-X³X⁴X⁵X⁶X⁷X⁸X⁹-3'

wherein X⁵ and X⁸ are guanosine, wherein X⁶ and X⁹ are adenosine, wherein X⁴ is uridine, wherein X³ is cytidine, and wherein X⁷ and X⁹ are independently adenosine, guanosine, cytidine, or uridine.

3. The composition of claim 1, wherein Z₁ and Z₃ do not contain any pyrimidines that are ribonucleotides.

4. The composition of claim 1, wherein Z₁ and Z₃ do not contain any ribonucleotides.

5. The composition of claim 1, wherein Z₁ and Z₃ are comprised of nucleotides, nucleotide analogues, or both, wherein the nucleotides and nucleotide analogues each have the structure



wherein each B is independently adenin-9-yl, cytosin-1-yl, guanin-9-yl, uracil-1-yl, uracil-5-yl, hypoxanthin-9-yl, thymine-1-yl, 5-methylcytosin-1-yl, 2,6-diaminopurin-9-yl, purin-9-yl, 7-deazaadenin-9-yl, 7-deazaguanin-9-yl, 5-propynylcytosin-1-yl, 5-propynyluracil-1-yl, isoguanin-9-yl, 2-aminopurin-9-yl, 6-methyluracil-1-yl, 4-thiouracil-1-yl, 2-pyrimidone-1-yl, quinazoline-2,4-dione-1-yl, xanthin-9-yl, N²-dimethylguanin-9-yl or a functional equivalent thereof,

wherein each V is independently an O, S, NH, or CH₂ group,

wherein each W is independently selected from the group consisting of substituted or unsubstituted C₁-C₁₀ straight chain or branched alkyl, C₂-C₁₀ straight chain or branched alkenyl, C₂-C₁₀ straight chain or branched alkynyl, C₁-C₁₀ straight chain or branched alkoxy, C₂-C₁₀ straight chain or branched alkenyloxy, and C₂-C₁₀ straight chain or branched alkynyloxy,

wherein D and E are residues which together form a phosphodiester or phosphorothioate diester bond between adjacent nucleosides or nucleoside analogues or together form an analogue of an internucleosidic bond.

6. The composition of claim 1, wherein Z_1 and Z_3 each independently contain from 3 to 40 nucleotides, nucleotide analogues, or a combination.

7. The composition of claim 1, wherein Z_2 contains one or several nucleotide analogues wherein each W is independently selected from the group consisting of C_1 - C_5 straight chain or branched alkyl, C_2 - C_5 straight chain or branched alkenyl, C_2 - C_5 straight chain or branched alkynyl, C_1 - C_5 straight chain or branched alkoxy, C_2 - C_5 straight chain or branched alkenyloxy, and C_2 - C_5 straight chain or branched C_2 - C_5 alkenyloxy.

8. The composition of claim 1, wherein the free 3' end is protected against exonuclease degradation.

9. The composition of claim 1, wherein in X^{12} W is independently NH_2 , OH-substituted C_1 - C_4 alkyl, OH-substituted C_2 - C_4 alkenyl, OH-substituted C_1 - C_4 alkoxy or OH-substituted C_2 - C_4 alkenyloxy.

10. The composition of claim 9, wherein in X^{12} W is independently NH_2 , methoxy, 2-hydroxyethoxy, allyloxy or allyl.

11. The composition of claim 1, wherein X^{12} is a ribonucleotide.

12. The composition of claim 1, wherein X^{13} and X^{14} , or a combination is a nucleotide analogue in which each W is independently C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_1 - C_4 alkoxy, C_2 - C_4 alkenyloxy, OH-substituted C_1 - C_4 alkyl, OH-substituted C_2 - C_4 alkenyl, OH-substituted C_1 - C_4 alkoxy, or OH-substituted C_2 - C_4 alkenyloxy.

13. The composition of claim 12, wherein X^{13} and X^{14} , or a combination is a nucleotide analogue in which each W is independently methoxy, 2-hydroxyethoxy or allyloxy.

14. The composition of claim 1, wherein the RNA substrate is selected from the group consisting of human dopamine D2 receptor mRNA, human brain cholecystokinin receptor mRNA, human serotonin 5-HT3 receptor mRNA, human alpha-2-macroglobulin receptor RNA, human tyrosine kinase-type receptor (HER2) mRNA, human interleukin 2 receptor beta chain mRNA, human MAD-3

mRNA, human bcl-1 mRNA, human bcl-2 mRNA, human cyclin F mRNA, human cyclin G1 mRNA, human bleomycin hydrolase mRNA, human acute myeloid leukemia 1 oncogene mRNA, human polycystic kidney disease 1 protein (PKD1) mRNA, transcripts of the bovine viral diarrhea virus, transcripts of the foot and mouth disease virus 3D gene and transcripts of the Epstein-Barr virus.

15. The composition of claim 1, wherein X^{15.1} is a ribonucleotide.

16. A method for the specific cleavage of an RNA substrate, the method comprising bringing into contact the composition of claim 1 and the RNA substrate.

17. The method of claim 16, wherein the RNA substrate is selected from the group consisting of human dopamine D2 receptor mRNA, human brain cholecystikinin receptor mRNA, human serotonin 5-HT3 receptor mRNA, human alpha-2-macroglobulin receptor RNA, human tyrosine kinase-type receptor (HER2) mRNA, human interleukin 2 receptor beta chain mRNA, human MAD-3 mRNA, human bcl-1 mRNA, human bcl-2 mRNA, human cyclin F mRNA, human cyclin G1 mRNA, human bleomycin hydrolase mRNA, human acute myeloid leukemia 1 oncogene mRNA, human polycystic kidney disease 1 protein (PKD1) mRNA, transcripts of the bovine viral diarrhea virus, transcripts of the foot and mouth disease virus 3D gene and transcripts of the Epstein-Barr virus.

18. A method of identifying the function of a gene, the method comprising

bringing into contact the composition of claim 1 and a cell containing the gene, wherein the composition reduces expression of the gene, and

observing any change in the cell.

19. A method of treating a disease that is associated with an RNA molecule, the method comprising administering to a subject having the disease the composition of claim 1, wherein the RNA substrate is the RNA molecule associated with the disease.

20. The method of claim 19 wherein the RNA molecule is an RNA molecule that is overexpressed.

1/8




Figure 1

2/8





Figure 2



U 16.1




A^{15.1}C^{16.1}I^{15.1}

Figure 3




FIGURE 4a




FIGURE 4b




FIGURE 5a




FIGURE 5b




FIGURE 6a.




FIGURE 6b




FIGURE 7a




FIGURE 7b




FIGURE 8a




FIGURE 8b

INTERNATIONAL SEARCH REPORT

Inte. national Application No

PCT/US 98/12570

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/11 C12N9/00 C07H21/00 A61K31/70 //C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 18312 A (VIMRX HOLDINGS LTD ; LUDWIG JANOS (DE); SPROAT BRIAN (DE)) 22 May 1997 cited in the application see page 4, line 15 - page 10, line 26 see claims see figures	1, 3-20
A	PERRIMAN R ET AL: "EXTENDED TARGET-SITE SPECIFICITY FOR A HAMMERHAED RIBOZYME" GENE, vol. 113, no. 2, 1992, pages 157-163, XP000267805 cited in the application see pages 161-162, paragraphs (e) and (f) --- -/-	1-20

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 November 1998

Date of mailing of the international search report

27/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/12570

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SINGH K K ET AL: "DESIGN OF HAMMERHEAD RIBOZYMES TO DISTINGUISH SINGLE BASE CHANGES IN SUBSTRATE RNA" ANTISENSE RESEARCH AND DEVELOPMENT; vol. 6, no. 3, 1996, pages 165-168, XP002020361 cited in the application see page 167, left-hand column, line 15 - line 25</p>	1
A	<p>SCOTT, W. ET AL.: "The crystal structure of an all-RNA hammerhead ribozyme: a proposed mechanism for RNA catalytic cleavage" CELL, vol. 81, 30 June 1995, pages 991-1002, XP002084034 cited in the application see page 995, left-hand column, line 16 - page 996, left-hand column, line 22</p>	1
A	<p>AMONTOV S V ET AL: "HAMMERHEAD MINIZYMES WITH HIGH CLEAVAGE ACTIVITY: A DIMERIC STRUCTURE AS THE ACTIVE CONFORMATION OF MINIZYMES" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 7, 21 February 1996, pages 1624-1628, XP002045193 cited in the application</p> <p>ORTIGAO J F R ET AL: "ANTISENSE EFFECT OF OLIGODEOXYNUCLEOTIDES WITH INVERTED TERMINAL INTERNUCLEOTIDIC LINKAGES: A MINIMAL MODIFICATION PROTECTING AGAINST NUCLEOLYTIC DEGRADATION" ANTISENSE RESEARCH AND DEVELOPMENT, vol. 2, no. 2, 1992, pages 129-146, XP000573884 cited in the application</p>	
P, X	<p>LUDWIG J ET AL: "Extending the cleavage rules for the hammerhead ribozyme: mutating adenosine15.1 to inosine15.1 changes the cleavage site specificity from N16.2U16.1H17 to N16.2C16.1H17." NUCLEIC ACIDS RESEARCH, (1998 MAY 15) 26 (10) 2279-85., XP002084035 see the whole document</p>	1-6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 12570

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 16 and 17 (as far as in vivo methods are concerned) and claims 19 and 20, are directed to a method of treatment of or of diagnostic practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/12570

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9718312 A	22-05-1997	DE 19542404 A	15-05-1997
		AU 7572096 A	05-06-1997
		EP 0866865 A	30-09-1998
<hr/>			